Overview: EBV Quantitative PCR TestIntroduction: The EBV Quantitative PCR Test measures Epstein-Barr virus DNA to monitor infection, causing fatigue or lymph node swelling. Following 2023 IDSA guidelines, it uses PCR for high sensitivity, aiding in infectious disease screening. This test is critical for guiding antiviral therapy, monitoring treatment response, and improving outcomes in virology for patients with suspected EBV infections.
Other Names: EBV Quant PCR Assay, Epstein-Barr Virus DNA Quantification Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: EBV PCR testing began in the 1990s with molecular diagnostics. Quantitative PCR emerged in the 2000s, improving monitoring accuracy for viral load.
Purpose: Quantifies EBV viral load, guides antiviral therapy, and monitors infection in patients with fatigue or lymph node swelling.
Test Parameters: 1. Epstein-Barr Virus DNA
Pretest Condition: No fasting required. Collect whole blood, serum, plasma, CSF, or saliva at any time. Report symptoms like fatigue or lymph node swelling, and list immunocompromising conditions.
Specimen: 2-5 mL whole blood (EDTA), 2-5 mL serum (SST), 2-4 mL plasma (EDTA), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, lymph node swelling, or immunocompromised states (e.g., HIV, transplant). Include current medications, especially antivirals.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for antiviral therapy.
Procedural Considerations: Uses quantitative PCR to measure EBV DNA levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low viral load or improper storage can cause false negatives. Contamination may cause false positives.
Clinical Significance: High viral load confirms active EBV infection, prompting antiviral therapy. Low or undetectable levels indicate treatment response or inactive infection.
Specialist Consultation: Consult an infectious disease specialist or hematologist for result interpretation.
Additional Supporting Tests: EBV VCA IgG/IgM, viral culture, or lymphocyte count to confirm infection status.
Test Limitations: False negatives may occur with low viral load. Results require clinical correlation.
References: IDSA EBV Guidelines, 2023; Clinical Infectious Diseases, Cohen JI, 2022.
